Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

MBX

MBX Biosciences Inc.

Sep 20 • 03:01PM ET

22.53

Dollar change +1.30
Percentage change 6.13	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Financials • Options • Save to Portfolio • Create Alert

Index	-	P/E	-	EPS (ttm)	-	Insider Own	53.70%	Shs Outstand	31.85M	Perf Week	-4.73%
Market Cap	717.65M	Forward P/E	-	EPS next Y	-	Insider Trans	98.80%	Shs Float	14.75M	Perf Month	-
Income	-	PEG	-	EPS next Q	-	Inst Own	-	Short Float	-	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	-	Perf Half Y	-
Book/sh	-3.07	P/B	-	EPS next Y	-	ROA	-	Short Interest	-	Perf Year	-
Cash/sh	1.74	P/C	12.99	EPS next 5Y	-	ROE	-	52W Range	20.29 - 26.08	Perf YTD	-4.73%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-13.60%	Beta	-
Dividend TTM	-	Quick Ratio	7.17	Sales past 5Y	0.00%	Gross Margin	-	52W Low	11.08%	ATR (14)	2.78
Dividend Ex-Date	-	Current Ratio	7.17	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	-	Volatility	- -
Employees	-	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-	Payout	-	Rel Volume	0.81	Prev Close	21.23
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	469.70K	Price	22.53
SMA20	3.33%	SMA50	3.33%	SMA200	3.33%	Trades		Volume	325,726	Change	6.13%

Sep-18-24 03:19AM	OrbiMed Advisors LLC Acquires New Stake in MBX Biosciences Inc (GuruFocus.com)
Sep-16-24 04:05PM	MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -8.46%
Sep-12-24 07:11PM	MBX Biosciences Announces Pricing of Initial Public Offering (GlobeNewswire)

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mathers Edward T	Director	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:28 PM
BASKETT FOREST	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:26 PM
Behbahani Ali	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:24 PM
Chang Carmen	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:23 PM
Florence Anthony A. Jr.	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:21 PM
Makhzoumi Mohamad	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:20 PM
Walker Paul Edward	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:18 PM
Yang Rick	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:17 PM
SANDELL SCOTT D	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:14 PM
ORBIMED ADVISORS LLC	Director	Sep 16 '24	Buy	16.00	750,000	12,000,000	3,158,428	Sep 17 08:13 PM
New Enterprise Associates 17,	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:12 PM
Frazier Life Sciences X, L.P.	10% Owner	Sep 16 '24	Buy	16.00	625,000	10,000,000	4,552,774	Sep 17 08:11 PM
Heron Patrick J	Director	Sep 16 '24	Buy	16.00	625,000	10,000,000	4,552,774	Sep 17 08:09 PM
Aynechi Tiba	Director	Sep 16 '24	Buy	16.00	750,000	12,000,000	2,136,335	Sep 17 08:05 PM
GORDON CARL L	Director	Sep 16 '24	Buy	16.00	750,000	12,000,000	3,158,428	Sep 17 08:05 PM

Open in Screener

KRRO

Korro Bio Inc.

Sep 20 • 03:01PM ET

35.07

Dollar change -3.43
Percentage change -8.91	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN VTWO VHT IWO IWC ITOT VTWV

Index	RUT	P/E	-	EPS (ttm)	-25.49	Insider Own	36.37%	Shs Outstand	8.02M	Perf Week	-15.35%
Market Cap	326.15M	Forward P/E	-	EPS next Y	-9.79	Insider Trans	5.57%	Shs Float	5.92M	Perf Month	-23.79%
Income	-92.22M	PEG	-	EPS next Q	-2.55	Inst Own	62.88%	Short Float	4.86%	Perf Quarter	-0.88%
Sales	0.00M	P/S	-	EPS this Y	82.24%	Inst Trans	-28.19%	Short Ratio	3.31	Perf Half Y	-46.05%
Book/sh	21.34	P/B	1.64	EPS next Y	-3.86%	ROA	-56.06%	Short Interest	0.29M	Perf Year	255.14%
Cash/sh	17.12	P/C	2.05	EPS next 5Y	-	ROE	-75.75%	52W Range	4.57 - 97.91	Perf YTD	-26.83%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-11.67%	ROI	-39.06%	52W High	-64.18%	Beta	3.85
Dividend TTM	-	Quick Ratio	13.28	Sales past 5Y	-26.84%	Gross Margin	-	52W Low	666.56%	ATR (14)	4.27
Dividend Ex-Date	-	Current Ratio	13.28	EPS Y/Y TTM	73.20%	Oper. Margin	0.00%	RSI (14)	36.74	Volatility	9.81% 10.12%
Employees	101	Debt/Eq	0.19	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	123.75
Option/Short	No / Yes	LT Debt/Eq	0.19	EPS Q/Q	83.89%	Payout	-	Rel Volume	0.87	Prev Close	38.50
Sales Surprise	-	EPS Surprise	-0.06%	Sales Q/Q	-	Earnings	Aug 13 AMC	Avg Volume	86.90K	Price	35.07
SMA20	-18.44%	SMA50	-19.74%	SMA200	-31.54%	Trades		Volume	64,951	Change	-8.91%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-14-24	Initiated	William Blair	Outperform	$180
Mar-28-24	Reiterated	H.C. Wainwright	Buy	$100 → $115
Feb-27-24	Initiated	BMO Capital Markets	Outperform	$120
Dec-04-23	Initiated	H.C. Wainwright	Buy	$100
Nov-29-23	Initiated	RBC Capital Mkts	Outperform	$70
Nov-10-23	Initiated	Piper Sandler	Overweight	$180
Feb-15-23	Downgrade	Chardan Capital Markets	Buy → Neutral
Feb-13-23	Downgrade	Cowen	Outperform → Market Perform
Sep-22-21	Downgrade	Goldman	Buy → Neutral	$12 → $9
Jan-27-21	Upgrade	JP Morgan	Neutral → Overweight	$56
Dec-22-20	Initiated	B. Riley Securities	Buy	$79
Jul-14-20	Initiated	Oppenheimer	Outperform	$36
May-18-20	Downgrade	JP Morgan	Overweight → Neutral	$27
Oct-28-19	Initiated	JP Morgan	Overweight	$25
Oct-28-19	Initiated	Goldman	Buy	$30
Oct-28-19	Initiated	Cowen	Outperform

Show Previous Ratings

Sep-16-24 08:00AM	Korro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates (GlobeNewswire)
Sep-10-24 08:00AM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-28-24 08:00AM	Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors (GlobeNewswire)
Aug-27-24 08:00AM	Korro to Participate in Upcoming September Investor and Scientific Conferences (GlobeNewswire)
Aug-13-24 04:01PM	Korro Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) +9.21%
08:00AM	Loading…
Jul-01-24 08:00AM	Korro Joins the Russell 2000 , Russell 3000 , and Russell Microcap Indexes (GlobeNewswire)
Jun-25-24 12:53PM	KRRO Stock Earnings: Korro Bio Beats EPS for Q4 2023 (InvestorPlace)
May-30-24 04:01PM	Korro to Participate in Upcoming June Investor and Scientific Conferences (GlobeNewswire)
May-20-24 02:30PM	Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference (GlobeNewswire)
May-14-24 10:55PM	KRRO Stock Earnings: Korro Bio Beats EPS for Q1 2024 (InvestorPlace) +5.43%
04:01PM	Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer (GlobeNewswire)
Apr-18-24 08:30AM	Korro Announces $70 Million Private Placement (GlobeNewswire)
Apr-01-24 04:01PM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire) -7.90%
Mar-26-24 04:01PM	Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress (GlobeNewswire) +18.43%
Feb-27-24 09:55AM	Wall Street Analysts Believe Korro Bio, Inc. (KRRO) Could Rally 86.94%: Here's is How to Trade (Zacks) -6.08%
08:00AM	Loading…
08:00AM	Korro to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-09-24 09:55AM	Does Korro Bio, Inc. (KRRO) Have the Potential to Rally 59.66% as Wall Street Analysts Expect? (Zacks)
Jan-18-24 08:00AM	Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio (GlobeNewswire) -5.98%
Jan-04-24 08:00AM	Korro to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-07-23 08:00AM	Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire) -14.67%
Nov-28-23 08:00AM	Korro Bio Appoints Dr. Rachel Meyers to Board of Directors (GlobeNewswire) +6.45%
Nov-03-23 03:31PM	UPDATE: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million (GlobeNewswire) +5.94%
12:19PM	Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million (GlobeNewswire)
Aug-10-23 04:01PM	Frequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results (Business Wire)
Jul-17-23 11:59AM	Frequency (FREQ) Up 77% on Merger Deal With Korro Bio (Zacks) -12.66%
Jul-14-23 11:22AM	Why Are Frequency Therapeutics Shares Surging Today (Benzinga) +77.47%
06:30AM	Korro Bio and Frequency Therapeutics Announce Merger Agreement (Business Wire)
May-12-23 04:01PM	Frequency Therapeutics Provides Business Updates and First Quarter 2023 Financial Results (Business Wire) -5.17%
Mar-10-23 07:30AM	Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
Feb-27-23 07:30AM	Frequency Therapeutics to Participate at Upcoming March Investor Conferences (Business Wire) +5.40%
01:55PM	Loading…
Feb-13-23 01:55PM	Hearing loss startup to cut more than half of staff in wake of trial failure (American City Business Journals) -80.54%
11:17AM	Frequency Therapeutics' Lead Hearing Loss Program Flunks, Shifts Focus To Multiple Sclerosis, Shares Plunge (Benzinga)
08:05AM	Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss (Business Wire)
Dec-19-22 07:30AM	Frequency Therapeutics Announces Formation of Clinical Advisory Board for Remyelination in Multiple Sclerosis Program (Business Wire)
Dec-15-22 07:30AM	Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Companys Second Therapeutic Candidate for Sensorineural Hearing Loss (Business Wire)
Nov-17-22 07:30AM	Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical Results (Business Wire) -10.05%
Nov-08-22 04:05PM	Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results (Business Wire) -9.51%
Oct-12-22 07:30AM	Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss (Business Wire) +7.47%
Aug-30-22 07:30AM	Frequency Therapeutics to Participate in September Investor and Medical Conferences (Business Wire)
Aug-09-22 04:05PM	Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results (Business Wire) -11.11% +9.00%
Jun-24-22 09:03AM	Frequency Therapeutics (NASDAQ:FREQ) one-year losses have grown faster than shareholder returns have fallen, but the stock jumps 41% this past week (Simply Wall St.) -7.59%
May-25-22 12:00PM	Frequency Therapeutics, Inc. (FREQ) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
May-18-22 07:30AM	Frequency Therapeutics to Participate in 2022 H.C. Wainwright Global Investment Conference (Business Wire) -9.02%
May-04-22 04:30PM	Frequency Therapeutics Provides Business Updates and First Quarter 2022 Financial Results (Business Wire)
Apr-22-22 07:30AM	Frequency Therapeutics to Participate in B. Riley Securities Neuro & Ophthalmology Investor Conference (Business Wire)
Apr-08-22 05:00PM	Frequency Exchange Corp. Virtually Closes the Market (PR Newswire) -8.82%
Mar-15-22 07:30AM	Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2021 Financial Results (Business Wire) +15.29%
Mar-10-22 06:35PM	Poseida Therapeutics, Inc. (PSTX) Beats Q4 Earnings and Revenue Estimates (Zacks) -13.70%
Feb-28-22 07:30AM	Frequency Therapeutics to Participate in Upcoming March 2022 Investor Conferences (Business Wire)
Jan-14-22 05:43AM	One Frequency Therapeutics, Inc. (NASDAQ:FREQ) insider upped their stake in the previous year (Simply Wall St.)
Jan-04-22 07:30AM	Frequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-28-21 02:38AM	Destra Investment Trust Buys ThredUp Inc, Etsy Inc, Riskified, Sells , , 2U Inc (GuruFocus.com) +5.28%
Dec-09-21 01:18PM	Frequency Therapeutics' Hearing Loss Candidate Shows Improved Speech Perception In Noise (Benzinga)
07:30AM	Frequency Therapeutics Shares Results from FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements in Noise (Business Wire)
Nov-30-21 05:53AM	Frequency Therapeutics (NASDAQ:FREQ) investors are sitting on a loss of 81% if they invested a year ago (Simply Wall St.)
Nov-15-21 12:25PM	Frequency Therapeutics, Inc. (FREQ) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:30AM	Frequency Therapeutics Provides Business Updates and Third Quarter 2021 Financial Results (Business Wire)
Nov-09-21 07:30AM	Frequency Therapeutics Holds Virtual R&D Event Highlighting Clinical Advancement of FX-322, a New Potential Restorative Treatment for Hearing Loss and In Vivo Data for Its Remyelination Program in Multiple Sclerosis (Business Wire)
Nov-08-21 03:00PM	Analysts Estimate Frequency Therapeutics, Inc. (FREQ) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-27-21 07:30AM	Frequency Therapeutics Virtual R&D Event to Detail FX-322 Clinical Advances, a New Program for Hearing Restoration and In Vivo Data from its MS Remyelination Program (Business Wire)
Oct-21-21 07:30AM	Frequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b Acquired Sensorineural Hearing Loss (SNHL) Study and FDA Agreement on Speech Perception as Primary Endpoint (Business Wire)
Oct-01-21 08:23AM	Do Insiders Own Lots Of Shares In Frequency Therapeutics, Inc. (NASDAQ:FREQ)? (Simply Wall St.)
Sep-22-21 11:18AM	Frequency Therapeutics' New Data Of Hearing Loss Candidate Fails To Impress Investors (Benzinga)
07:30AM	Frequency Therapeutics Announces New FX-322 Results Showing That Additional Study Participants Gain Hearing Improvements at Later Time Points (Business Wire)
Sep-08-21 07:30AM	Frequency Therapeutics to Present at Upcoming Investor Conferences (Business Wire)
Aug-30-21 05:10PM	Lifshitz Law Firm, P.C. Announces Investigations of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Frequency Therapeutics, Inc. (NasdaqGS: FREQ), RLX Technology Inc. (NYSE: RLX), and Washington Prime Group, Inc. (NYSE: WPG) (ACCESSWIRE)
Aug-12-21 04:06PM	Moore Kuehn, PLLC Encourages Investors of FREQ to Contact Law Firm (Newsfile)
08:45AM	Frequency Therapeutics, Inc. (FREQ) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Frequency Therapeutics Provides Business Updates and Second Quarter 2021 Financial Results (Business Wire)
Aug-04-21 03:00PM	Analysts Estimate Frequency Therapeutics, Inc. (FREQ) to Report a Decline in Earnings: What to Look Out for (Zacks)
Aug-02-21 03:05PM	CLASS ACTION UPDATE for JRVR, FREQ and QFIN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders (ACCESSWIRE)
02:30PM	Final Deadline Alert: Frequency Therapeutics, Inc. (FREQ) Class Action and Last Chance for Investors to Actively Participate - Bronstein, Gewirtz & Grossman, LLC (ACCESSWIRE)
12:30PM	SHAREHOLDER ALERT: FREQ RKT QFIN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines (ACCESSWIRE)
12:30PM	FINAL DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Frequency Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (ACCESSWIRE)
11:00AM	FREQ Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Frequency Therapeutics, Inc. (FREQ) Shareholders of Class Action and Lead Plaintiff Deadline: August 2, 2021 (ACCESSWIRE)
10:00AM	The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FREQ, RKT and BZ (ACCESSWIRE)
09:16AM	FREQ Final Deadline Today: Rosen, National Trial Lawyers, Encourages Frequency Therapeutics, Inc. Investors to Secure Counsel Before Important August 2 Deadline in Securities Class Action - FREQ (Newsfile)
09:09AM	DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Frequency Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (Newsfile)
05:50AM	The Gross Law Firm Announces Class Actions on Behalf of Shareholders of FREQ, RLX and DIDI (ACCESSWIRE)
03:27AM	Frequency Therapeutics (NASDAQ:FREQ) Has Debt But No Earnings; Should You Worry? (Simply Wall St.)
Aug-01-21 10:38AM	FREQUENCY DEADLINE ALERT: Faruqi & Faruqi LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Frequency To Contact Him Directly To Discuss Their Options (GlobeNewswire)
06:36AM	FREQ FINAL DEADLINE: ROSEN, A TOP RANKED FIRM, Encourages Frequency Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline Tomorrow in Securities Class Action - FREQ (Newsfile)
Jul-30-21 08:49PM	DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Frequency Therapeutics, Inc. and Encourages Investors to Contact the Firm (Business Wire)
07:19PM	Frequency Therapeutics, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm (GlobeNewswire)
07:10PM	SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Frequency Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - FREQ (ACCESSWIRE)
05:15PM	FREQ Final Deadline Monday: Rosen, Leading Trial Attorneys, Encourages Frequency Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important August 2 Deadline in Securities Class Action - FREQ (Newsfile)
02:57PM	FREQ LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Frequency Therapeutics, Inc. (Newsfile)
01:30PM	FINAL DEADLINE IMMINENT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Frequency Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (ACCESSWIRE)
12:40PM	The Gross Law Firm Announces Class Actions on Behalf of Shareholders of FREQ, OCGN and BLCT (ACCESSWIRE)
11:30AM	The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Frequency Therapeutics, Inc. (FREQ) (Business Wire)
11:30AM	CLASS ACTION UPDATE for CCIV, FREQ and RLX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders (ACCESSWIRE)
11:00AM	FREQ INVESTOR ALERT: Shareholder Lawsuit Deadline Approaching (ACCESSWIRE)
10:00AM	SHAREHOLDER ALERT: FREQ RLX DIDI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines (ACCESSWIRE)
10:00AM	FREQ Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Frequency Therapeutics, Inc. (FREQ) Shareholders of Class Action and Lead Plaintiff Deadline: August 2, 2021 (GlobeNewswire)
09:30AM	MONDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Frequency Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (Newsfile)
09:00AM	FREQUENCY THERAPEUTICS SHAREHOLDERS: August 2, 2021 Filing Deadline in Class Action - Contact Lieff Cabraser (ACCESSWIRE)
05:18AM	FREQ ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 2, 2021 in the Class Action Filed on Behalf of Frequency Therapeutics, Inc. Limited Shareholders (Newsfile)
Jul-29-21 08:47PM	Frequency Class Action Reminder (Newsfile)
05:29PM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Frequency Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 2, 2021 - FREQ (Newsfile)
04:02PM	MONDAY DEADLINE: Investors with Substantial Losses Have Opportunity to Lead the Frequency Therapeutics, Inc. Class Action Lawsuit - FREQ (PR Newswire)

Korro Bio, Inc. is an RNA editing company, which engages in the discovery and development of genetic medicines. The company was founded by Nessan Bermingham, Jean-Francois Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Colletti Steve	Former Officer	Aug 30 '24	Proposed Sale	49.24	10,303	507,326		Aug 30 05:28 PM
New Enterprise Associates 17,	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
BASKETT FOREST	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
Florence Anthony A. Jr.	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
Walker Paul Edward	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
Chang Carmen	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
Mathers Edward T	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
Yang Rick	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
Makhzoumi Mohamad	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
SANDELL SCOTT D	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
Atlas Venture Opportunity Fund	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	195,074	Apr 23 05:23 PM
Lucchino David L.	Director	Nov 22 '23	Sale	37.69	1,156	43,573	22,150	Nov 27 08:48 PM
Lucchino David L.	Director	Nov 10 '23	Sale	41.97	968	40,632	23,306	Nov 22 04:05 PM

MBX

MBX Biosciences Inc.

KRRO

Korro Bio Inc.

Upgrade your FINVIZ experience